PD-1/PD-L1 immunotherapy has achieved a remarkable curative effect in the treatment of malignant tumors, such as renal clear cell carcinoma, melanoma, and non-small cell lung cancer. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.